Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis
Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis
The primary objective of this study is to evaluate, through clinical parameters, the
 effectiveness of your medicine topic Maxinom ® (dexamethasone, neomycin and polymyxin B -
 Union Chemicals), comparing it to the topical medication Maxitrol ® (dexamethasone, neomycin
 and polymyxin B - Alcon ) by the percentage of improvement (sustained response rate) at the
 end of treatment, among the products studied.
1. Evaluation of isolated signs and symptoms during treatment, with a record of individual
 scores for each parameter and observation

 2. Statistical comparison of drug safety, by recording qualitative and quantitative
 parameters related to adverse effects occurring during treatment.
Inclusion Criteria:

 -  Patients who agree with all study procedures and sign, by his own free will, IC;

 -  Adult patients, regardless of gender, ethnicity or social status, with good
 mental health;

 -  Patients who present at screening visit, picture of acute bacterial
 conjunctivitis diagnosed clinically.

 Exclusion Criteria:

 -  Patients with clinical diagnosis or suspicion of conjunctivitis due to any process
 that is not due to bacterial infection, such as infections by fungi, protozoa, viruses
 and allergic conjunctivitis;

 -  Patients with known hypersensitivity to any component of the formulas of the
 study drugs;

 -  Patients with a history or clinical diagnosis of other lesions that may affect
 the outcome, such as glaucoma, corneal ulcer or scars;

 -  Concomitant use of ocular medication other than the study;

 -  Pregnant or lactating women;

 -  Being or having been treated for any type of conjunctivitis within 15 days and
 have finished treatment or less than 07 days